Lucid Diagnostics Inc. (LUCD): Nasdaq/NYSE listing notice — Lucid Diagnostics receives Nasdaq delisting notice for equity shortfall, plans transfer to Capital Market

Lucid Diagnostics Inc.

Nasdaq notified Lucid of non-compliance with Global Market equity standard requiring $10M minimum equity; reported equity was $2.556M as of Sep 30, 2023.
Company will apply to transfer its common stock listing to Nasdaq Capital Market, where it believes it will satisfy continued listing requirements.
The notice does not immediately affect stock trading; shares continue to trade under symbol LUCD.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Lucid Diagnostics Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(b)(1)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5450(b)(1)(A)

Exact text from the filing

continued listing under the Equity Standard. Because the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023 reported stockholders’ equity of $2,556,000 (and because the Company does not meet the alternative standards for Market Value or Total Assets/Total Revenue), the Company has fallen out of compliance with the continued

View on SEC.gov

Browse all listing & compliance notices →

Lucid Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-042669

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.